Nuvectis Pharma, Inc.

Listed Company

NVCTCIK 0001875558NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-26.44M

Total Assets

$31.71M

Equity

$18.41M

Shares Out

26.53M

Op. Cash Flow

$-16.01M

NVCT$19.14+139.79% · past yearDBEQ Basic

Daily closing prices

Business

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for oncology with unmet medical needs. The company's lead product candidate is NXP900, a small-molecule inhibitor of SRC and YES1 kinases currently in Phase 1b clinical trials for solid tumors, with planned combination studies alongside EGFR and ALK inhibitors. Nuvectis operates a single reportable segment and operates globally through licensed intellectual property, third-party manufacturers, and clinical research organizations.

Summary from 10-K filed 2026-02-11

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	18	13	15	13	10
General and administrative	9	7	8	6	3
OPERATING LOSS	−28	−20	−23	−19	−13
Finance income	1	847,000	637,000	149,000	4,000
NET LOSS	−26	−19	−22	−19	−13
EFFECT OF WARRANTS MODIFICATION, see Note 6	−2	—	—	—	—
TOTAL NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	−29	−19	−22	−19	−13
BASIC NET LOSS PER COMMON SHARE OUTSTANDING, see Note 8	−1.32	−1.11	−1.43	−1.51	−3.02
DILUTED NET LOSS PER COMMON SHARE OUTSTANDING, see Note 8	−1.32	−1.11	−1.43	−1.51	−3.02
Basic weighted average number of common shares outstanding	22	17	16	13	4
Diluted weighted average number of common shares outstanding	22	17	16	13	4

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	32	19	19	20	6
Other current assets	75,000	74,000	59,000	412,000	91,000
TOTAL CURRENT ASSETS	32	19	19	20	6
TOTAL ASSETS	32	19	19	20	7
Accounts payables	6	2	3	3	1
Accrued liabilities	115,000	840,000	415,000	445,000	395,000
Employee compensation and benefits	7	6	4	2	142,000
TOTAL CURRENT LIABILITIES	13	9	7	6	2
TOTAL LIABILITIES	13	9	7	6	2
COMMITMENTS AND CONTINGENCIES, see Note 3	—	—	—	—	—
Common Shares, $0.00001 par value - 60,000,000 shares authorized as of December 31, 2025, and December 31, 2024, 25,676,798, and 19,495,683 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	—	—	—	—	—
Additional paid in capital	118	83	66	46	2
Accumulated deficit	−100	−73	−54	−32	−13
TOTAL SHAREHOLDERS' EQUITY	18	10	12	14	−11
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	32	19	19	20	7

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−26	−19	−22	−19	−13
Cost of share-based payments	6	5	5	2	2
Increase in other current assets	−1,000	−15,000	353,000	−321,000	−91,000
Increase/(decrease) in accounts payable	4	−273,000	−139,000	2	—
(Decrease)/increase in accrued liabilities	−725,000	425,000	−30,000	338,000	—
Increase in employee compensation and benefits	1	2	1	2	—
Net cash used in operating activities	−16	−12	−16	−14	−10
Net cash provided by (used in) investing activities	—	—	0	0	—
Net cash provided by financing activities	29	12	15	28	15
INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	13	−593,000	−867,000	14	6

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Nuvectis Pharma, Inc.'s CIK number?

Nuvectis Pharma, Inc.'s SEC CIK number is 0001875558 (1875558). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Nuvectis Pharma, Inc.'s SEC filings?

All of Nuvectis Pharma, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Nuvectis Pharma, Inc. last report earnings?

Nuvectis Pharma, Inc. (NVCT) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-055264). This is Nuvectis Pharma, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Nuvectis Pharma, Inc.'s most recent earnings 8-K?

Nuvectis Pharma, Inc.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001104659-26-055264. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Nuvectis Pharma, Inc.'s latest earnings 8-K →
Look up any company's CIK number →